Robert N. Wilson - Mar 20, 2023 Form 4 Insider Report for CalciMedica, Inc. /DE/ (CALC)

Role
Director
Signature
By John Dunn, Attorney-in-Fact
Stock symbol
CALC
Transactions as of
Mar 20, 2023
Transactions value $
$0
Form type
4
Date filed
3/22/2023, 08:52 PM
Next filing
Jun 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CALC Common Stock Award +182K 182K Mar 20, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CALC Director Stock Option (right to buy) Award +23.6K 23.6K Mar 20, 2023 Common Stock 23.6K $6.60 Direct F2, F3, F4
transaction CALC Director Stock Option (right to buy) Award +5.76K 5.76K Mar 20, 2023 Common Stock 5.76K $7.99 Direct F3, F5, F6, F7
transaction CALC Director Stock Option (right to buy) Award +5.76K 5.76K Mar 20, 2023 Common Stock 5.76K $7.99 Direct F3, F6, F7
transaction CALC Director Stock Option (right to buy) Award +7.58K 7.58K Mar 20, 2023 Common Stock 7.58K $17.34 Direct F3, F5, F8
transaction CALC Director Stock Option (right to buy) Award +1.49K 1.49K Mar 20, 2023 Common Stock 1.49K $17.34 Direct F3, F5, F9
transaction CALC Warrant Award +8.59K 8.59K Mar 20, 2023 Common Stock 8.59K $27.94 Direct F10, F11
transaction CALC Warrant Award +8.59K 8.59K Mar 20, 2023 Common Stock 8.59K $27.94 Direct F10, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Received in exchange for 6,307,451 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.
F2 Beginning on June 15, 2020, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.
F3 Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.
F4 Received in exchange for a stock option to acquire 817,964 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F5 Beginning on November 22, 2022, the shares subject to the option vest in a series of twelve (12) successive equal monthly installments.
F6 Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.
F7 Received in exchange for a stock option to acquire 200,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F8 Received in exchange for a stock option to acquire 263,107 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F9 Received in exchange for a stock option to acquire 51,692 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F10 Immediately exercisable.
F11 Received in exchange for a warrant to purchase 298,321 shares of common stock of CalciMedica pursuant to the Merger Agreement.